277 related articles for article (PubMed ID: 21360850)
1. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma.
Yodono H; Matsuo K; Shinohara A
Anticancer Drugs; 2011 Mar; 22(3):277-82. PubMed ID: 21360850
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.
Maeda N; Osuga K; Higashihara H; Tomoda K; Mikami K; Nakazawa T; Nakamura H; Tomiyama N
Cardiovasc Intervent Radiol; 2012 Feb; 35(1):82-9. PubMed ID: 21203761
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
[TBL] [Abstract][Full Text] [Related]
4. Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
Shirono T; Iwamoto H; Niizeki T; Shimose S; Nakano M; Satani M; Okamura S; Noda Y; Kamachi N; Kuromatsu R; Sakai M; Nomiyama M; Kuwano T; Tanaka M; Koga H; Torimura T
Oncology; 2019; 96(2):79-86. PubMed ID: 30293080
[TBL] [Abstract][Full Text] [Related]
5. Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma.
Nishikawa H; Osaki Y; Kita R; Kimura T; Ohara Y; Takeda H; Sakamoto A; Saito S; Nishijima N; Nasu A; Komekado H; Nishiguchi S
Oncol Rep; 2014 Jan; 31(1):65-72. PubMed ID: 24220763
[TBL] [Abstract][Full Text] [Related]
6. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma.
Hao MZ; Lin HL; Chen QZ; Hu YB; Chen JB; Zheng JX; Zhou D; Zhang H
J Dig Dis; 2017 Jan; 18(1):31-39. PubMed ID: 27987344
[TBL] [Abstract][Full Text] [Related]
8. Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature.
Takaki Y; Kaminou T; Shabana M; Ihaya T; Otsubo K; Ogawa T
Hepatogastroenterology; 2008; 55(81):202-6. PubMed ID: 18507107
[TBL] [Abstract][Full Text] [Related]
9. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion.
Kamada K; Nakanishi T; Kitamoto M; Aikata H; Kawakami Y; Ito K; Asahara T; Kajiyama G
J Vasc Interv Radiol; 2001 Jul; 12(7):847-54. PubMed ID: 11435541
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma.
Maeda S; Shibata J; Fujiyama S; Tanaka M; Noumaru S; Sato K; Tomita K
Hepatogastroenterology; 2003; 50(51):809-13. PubMed ID: 12828090
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for the benefit of triple-drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma.
He M; Li Q; Shen J; Tan G; Li Q; Lai J; Wei W; Zhang Y; Zou R; Chen M; Guo R; Shi M
Cancer Med; 2019 Aug; 8(9):4200-4213. PubMed ID: 31207163
[TBL] [Abstract][Full Text] [Related]
12. Effect of transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma.
Yamasaki T; Saeki I; Harima Y; Zaitsu J; Maeda M; Tanimoto H; Iwamoto T; Hidaka I; Urata Y; Ishikawa T; Takami T; Yamaguchi Y; Uchida K; Terai S; Sakaida I
J Gastroenterol; 2012 Jun; 47(6):715-22. PubMed ID: 22322658
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
[TBL] [Abstract][Full Text] [Related]
14. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma.
Sahara S; Kawai N; Sato M; Minamiguchi H; Nakai M; Takasaka I; Nakata K; Ikoma A; Sawa N; Sonomura T; Shirai S
Jpn J Radiol; 2010 Jun; 28(5):362-8. PubMed ID: 20585924
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
[TBL] [Abstract][Full Text] [Related]
17. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization.
Chen CS; Li FK; Guo CY; Xiao JC; Hu HT; Cheng HT; Zheng L; Zong DW; Ma JL; Jiang L; Li HL
Oncotarget; 2016 Feb; 7(6):7241-52. PubMed ID: 26769845
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of a CDDP-epirubicin-Lipiodol emulsion on advanced hepatocellular carcinoma.
Ichida T; Kato M; Hayakawa A; Ito S; Mori S; Sato T; Sugitani S; Sato H; Watanabe M; Asakura H
Cancer Chemother Pharmacol; 1994; 33 Suppl():S74-8. PubMed ID: 8137488
[TBL] [Abstract][Full Text] [Related]
19. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial.
Aramaki O; Takayama T; Moriguchi M; Sakamoto H; Yodono H; Kokudo N; Yamanaka N; Kawasaki S; Sasaki Y; Kubota K; Otsuji E; Tanaka S; Matsuyama Y; Fujii M;
Eur J Cancer; 2021 Nov; 157():373-382. PubMed ID: 34563992
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Zuo CH; Xia M; Liu JS; Qiu XX; Lei X; Xu RC; Liu HC; Li JL; Li YG; Li QL; Xiao H; Hong Y; Wang XH; Zhu HZ; Wu QF; Burns M; Liu C
Asian Pac J Cancer Prev; 2015; 16(1):245-51. PubMed ID: 25640360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
